115 related articles for article (PubMed ID: 3752939)
21. 4,6-Benzylidene-D-glucose, a benzaldehyde derivative that inhibits protein synthesis but not mitosis of NHIK 3025 cells.
Pettersen EO; Dornish JM; Rønning OW
Cancer Res; 1985 May; 45(5):2085-91. PubMed ID: 3986764
[TBL] [Abstract][Full Text] [Related]
22. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
23. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
24. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
26. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the anti-Leishmania effect induced by cisplatin, an anticancer drug.
Tavares J; Ouaissi M; Ouaissi A; Cordeiro-da-Silva A
Acta Trop; 2007 Aug; 103(2):133-41. PubMed ID: 17658446
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV
Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition by benzaldehyde of the uptake of nucleosides and sugar into simian virus 40-transformed cells.
Watanuki M; Sakaguchi K
Cancer Res; 1980 Jul; 40(7):2574-9. PubMed ID: 6248209
[TBL] [Abstract][Full Text] [Related]
32. Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.
Ducore JM; Erickson LC; Zwelling LA; Laurent G; Kohn KW
Cancer Res; 1982 Mar; 42(3):897-902. PubMed ID: 7199380
[TBL] [Abstract][Full Text] [Related]
33. Cis DDP in combination with selenium and sulfur. Subcellular effect in kidney cells. Electron microprobe study.
Berry JP; Lespinats G
J Submicrosc Cytol Pathol; 1988 Jan; 20(1):59-65. PubMed ID: 3370622
[TBL] [Abstract][Full Text] [Related]
34. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
35. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma.
Berry JP; Pauwells C; Tlouzeau S; Lespinats G
Cancer Res; 1984 Jul; 44(7):2864-8. PubMed ID: 6539165
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of DNA cross-linking in normal and neoplastic mouse tissues following treatment with cis-diamminedichloroplatinum(II) in vivo.
Murray D; Jenkins WT; Meyn RE
Cancer Res; 1985 Dec; 45(12 Pt 1):6446-52. PubMed ID: 4063992
[TBL] [Abstract][Full Text] [Related]
38. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
39. Increased effect of benzaldehyde by exchanging the hydrogen in the formyl group with deuterium.
Pettersen EO; Larsen RO; Børretzen B; Dornish JM; Oftebro R
Anticancer Res; 1991; 11(1):369-73. PubMed ID: 2018372
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.
Wallner KE; DeGregorio MW; Li GC
Cancer Res; 1986 Dec; 46(12 Pt 1):6242-5. PubMed ID: 3779644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
